Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Bonacia is a UK-based pharmaceutical company that operates as a subsidiary of Aspire Pharma. The company is primarily focused on the distribution and commercialization of specialized pain management therapeutics, most notably its branded morphine sulfate oral solution marketed under the name Bonacia. As an integral part of the Aspire Pharma group, Bonacia leverages centralized regulatory and supply chain capabilities to provide niche medicinal products to the UK healthcare market. The company specializes in value-added medicines and generic formulations tailored for specific patient populations, particularly in palliative and chronic pain care. Following the acquisition of its parent company by H.I.G. Capital in 2021, Bonacia remains an active entity within a broad portfolio of specialty pharmaceutical assets. Its products are widely utilized across the National Health Service (NHS) for the management of severe pain conditions.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Bonacia.